Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

Àü¸³¼±ºñ´ëÁõ ȯÀÚ¿¡¼­¥á-Â÷´ÜÁ¦ ¹× Finasteride º´¿ëÄ¡·á¿¡ µû¸¥ PSAÀÇ º¯È­ ¾ç»ó: 3³â°£ ÃßÀû°üÂû °á°ú The Changing Pattern of Serum Prostate Specific Antigen in Patients with Benign Prostatic Hyperplasia after Combined Treatment with Finasteride and ¥á-blockers: the 3 Year Follow-up Data

´ëÇѺñ´¢±â°úÇÐȸÁö 2006³â 47±Ç 4È£ p.372 ~ 376
¼Òº´Çö, Á¤º´ÇÏ, ÀÌÀç¼®,
¼Ò¼Ó »ó¼¼Á¤º¸
¼Òº´Çö ( Soh Byung-Hyun ) 
¿¬¼¼´ëÇб³ ÀÇ°ú´ëÇÐ ºñ´¢±â°úÇб³½Ç

Á¤º´ÇÏ ( Chung Byung-Ha ) 
¿¬¼¼´ëÇб³ ÀÇ°ú´ëÇÐ ºñ´¢±â°úÇб³½Ç
ÀÌÀç¼® ( Lee Jae-Seok ) 
¿¬¼¼´ëÇб³ ÀÇ°ú´ëÇÐ ºñ´¢±â°úÇб³½Ç

Abstract


Purpose: Some recent studies have demonstrated that finasteride, a well- known 5¥á-reductase inhibitor, can decrease prostate specific antigen(PSA) by approximately 50% during the first 1 year of treatment. We investigated how long-term treatment with finasteride and ¥á-blockers impacts on the serum PSA level of men whose final diagnosis was benign prostatic hyperplasia(BPH).

Materials and Methods: In a retrospective trial, we evaluated a total of 293 men with lower urinary tract symptoms(LUTS) that were suggestive of BPH. These men were divided into two treatment groups: group A was treated with ¥á-blockers and group C was treated with a combination of finasteride and ¥á-blocker. Comparisons of the two groups were performed by using independent t-tests. The changes in the PSA concentrations from baseline to the time of the final measurements were determined by repeated measures of ANOVA.

Results: There was no significant difference in the baseline PSA between the two groups. A statistically significant reduction in the PSA levels was observed at 2 years in C group(p£¼0.05), whereas any significant increase were not observed in group A(p£¾0.05). In group A, the repeatedly measured PSA levels were 2.67, 2.40, 2.41 and 2.42, respectively. In C group, these were 3.22, 2.09, 1.81 and 1.71 respectively.

Conclusions: Our data showed that there was no clinically significant effect of long term treatment with ¥á-blocker on the PSA levels. However, finasteride had significant effect on the serum PSA level during first two years of treatment. (Korean J Urol 2006;47:372-376)

Å°¿öµå

Prostatic hyperplasia;Adrenergic antagonist;Reductase;Prostate specific antigen

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

   

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS